Drug Profile
Research programme: RNAi therapeutics - Arbutus
Alternative Names: LNP-siRNA therapeutics - Arbutus; TKM-ALDH; TKM-GSD; TKM-HTG; TKM-MarburgLatest Information Update: 17 Apr 2019
Price :
$50
*
At a glance
- Originator Protiva Biotherapeutics
- Developer Arbutus Biopharma
- Class Antihyperlipidaemics; Antineoplastics; Antivirals; Drug withdrawal therapies; Hepatoprotectants; Small interfering RNA
- Mechanism of Action COPS5 protein inhibitors; RNA interference; WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Alcoholism; Hypertriglyceridaemia; Marburg virus disease; Non-alcoholic steatohepatitis; Solid tumours
- No development reported Lysosomal storage diseases
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lysosomal storage diseases in USA (Parenteral)
- 21 Mar 2017 Suspended - Preclinical for Alcoholism (TKM ALDH) in USA (Parenteral) (Arbutus 10-K 2017)
- 21 Mar 2017 Suspended - Preclinical for Hypertriglyceridaemia (TKM HTG) in USA (Parenteral) (Arbutus 10-K 2017)